These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 35103115)
61. Immunomodulation of Mesenchymal Stem Cells in Acute Lung Injury: From Preclinical Animal Models to Treatment of Severe COVID-19. Li JP; Wu KH; Chao WR; Lee YJ; Yang SF; Chao YH Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897770 [TBL] [Abstract][Full Text] [Related]
62. Mesenchymal stem cell therapy for COVID-19. Sengul F; Ozturk B; Vatansev H Am J Stem Cells; 2021; 10(5):79-89. PubMed ID: 35103115 [TBL] [Abstract][Full Text] [Related]
63. The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect. Can A; Coskun H Stem Cells Transl Med; 2020 Nov; 9(11):1287-1302. PubMed ID: 32779878 [TBL] [Abstract][Full Text] [Related]
64. May mesenchymal stem cell transplantation be a solution for COVID-19 induced cytokine storm? Sütlüoğlu H; Özdemir Ö World J Transplant; 2021 Aug; 11(8):344-355. PubMed ID: 34447671 [TBL] [Abstract][Full Text] [Related]
65. Perspectives on mesenchymal stem/progenitor cells and their derivates as potential therapies for lung damage caused by COVID-19. Klimczak A World J Stem Cells; 2020 Sep; 12(9):1013-1022. PubMed ID: 33033561 [TBL] [Abstract][Full Text] [Related]
66. Potency of Mesenchymal Stem Cell and Its Secretome in Treating COVID-19. Chouw A; Milanda T; Sartika CR; Kirana MN; Halim D; Faried A Regen Eng Transl Med; 2022; 8(1):43-54. PubMed ID: 33723519 [TBL] [Abstract][Full Text] [Related]
67. Cell therapy in patients with COVID-19 using Wharton's jelly mesenchymal stem cells: a phase 1 clinical trial. Saleh M; Vaezi AA; Aliannejad R; Sohrabpour AA; Kiaei SZF; Shadnoush M; Siavashi V; Aghaghazvini L; Khoundabi B; Abdoli S; Chahardouli B; Seyhoun I; Alijani N; Verdi J Stem Cell Res Ther; 2021 Jul; 12(1):410. PubMed ID: 34271988 [TBL] [Abstract][Full Text] [Related]
68. The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical COVID-19 Patients: A Prospective Double Controlled Trial. Adas G; Cukurova Z; Yasar KK; Yilmaz R; Isiksacan N; Kasapoglu P; Yesilbag Z; Koyuncu ID; Karaoz E Cell Transplant; 2021; 30():9636897211024942. PubMed ID: 34180719 [TBL] [Abstract][Full Text] [Related]
69. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. Rosas IO; Bräu N; Waters M; Go RC; Hunter BD; Bhagani S; Skiest D; Aziz MS; Cooper N; Douglas IS; Savic S; Youngstein T; Del Sorbo L; Cubillo Gracian A; De La Zerda DJ; Ustianowski A; Bao M; Dimonaco S; Graham E; Matharu B; Spotswood H; Tsai L; Malhotra A N Engl J Med; 2021 Apr; 384(16):1503-1516. PubMed ID: 33631066 [TBL] [Abstract][Full Text] [Related]
70. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. Shi L; Huang H; Lu X; Yan X; Jiang X; Xu R; Wang S; Zhang C; Yuan X; Xu Z; Huang L; Fu JL; Li Y; Zhang Y; Yao WQ; Liu T; Song J; Sun L; Yang F; Zhang X; Zhang B; Shi M; Meng F; Song Y; Yu Y; Wen J; Li Q; Mao Q; Maeurer M; Zumla A; Yao C; Xie WF; Wang FS Signal Transduct Target Ther; 2021 Feb; 6(1):58. PubMed ID: 33568628 [TBL] [Abstract][Full Text] [Related]
71. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series. Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427 [TBL] [Abstract][Full Text] [Related]
72. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. Veiga VC; Prats JAGG; Farias DLC; Rosa RG; Dourado LK; Zampieri FG; Machado FR; Lopes RD; Berwanger O; Azevedo LCP; Avezum Á; Lisboa TC; Rojas SSO; Coelho JC; Leite RT; Carvalho JC; Andrade LEC; Sandes AF; Pintão MCT; Castro CG; Santos SV; de Almeida TML; Costa AN; Gebara OCE; de Freitas FGR; Pacheco ES; Machado DJB; Martin J; Conceição FG; Siqueira SRR; Damiani LP; Ishihara LM; Schneider D; de Souza D; Cavalcanti AB; Scheinberg P; BMJ; 2021 Jan; 372():n84. PubMed ID: 33472855 [TBL] [Abstract][Full Text] [Related]
74. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. Salama C; Han J; Yau L; Reiss WG; Kramer B; Neidhart JD; Criner GJ; Kaplan-Lewis E; Baden R; Pandit L; Cameron ML; Garcia-Diaz J; Chávez V; Mekebeb-Reuter M; Lima de Menezes F; Shah R; González-Lara MF; Assman B; Freedman J; Mohan SV N Engl J Med; 2021 Jan; 384(1):20-30. PubMed ID: 33332779 [TBL] [Abstract][Full Text] [Related]
75. Pathophysiology and treatment strategies for COVID-19. Kumar M; Al Khodor S J Transl Med; 2020 Sep; 18(1):353. PubMed ID: 32933536 [TBL] [Abstract][Full Text] [Related]